Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — Q1 2026 Earnings Presentation
19 slides from Niagen Bioscience's earnings presentation, May 6, 2026
Slide 1: Niagen Bioscience Earnings Presentation First Quarter 2026
Niagen Bioscience, Inc. Earnings Presentation First Quarter 2026 Nasdaq: NAGE | May 6, 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act
Slide 3: Table of Contents & Leadership Team
Table of Contents & Leadership Team 1. Highlights Rob Fried Ozan Pamir Andrew Shao 2. Financial Results & Outlook Chief Executive Officer Chief Financial Officer SVP, Global Regulatory & Scientific Affairs 3.Scientific Updates Carlos Lopez Michiko Kelley 4.Contact Information SVP, General Counsel Ch
Slide 4: First Quarter 2026 Highlights
First Quarter 2026 Highlights $31.5 million net sales 63.5% gross profit margin $6.3 million net income Diluted EPS of $0.07 $3.8 million Adjusted EBITDA(1) $66.5 million cash, no outstanding borrowings (1) See slide 12 for the non-GAAP reconciliation 4
Slide 5: Operational Execution Supported Q1 2026 Performance
Operational Execution Supported Q1 2026 Performance Enterprise • Completed divestiture of Analytical Reference Standards and Services operating segment in an all-cash transaction, further streamlining operations and reinforcing focus on core NAD+ science and commercial growth • Board of directors ap
Slide 6: Performance Driven by Strong E-Commerce Performance
Performance Driven by Strong E-Commerce Performance Q1 2026 Q1 2026 Net Sales Y/Y Growth Takeaways • Excluding the impact of the divested segment in both periods, Total Niagen Bioscience $31.5M 3% net sales increased approximately 5% YoY • Consistent E-commerce performance delivering 14% growth Tru
Slide 7: Q1 2026: Continued Profitability and Disciplined Operations
Q1 2026: Continued Profitability and Disciplined Operations Delivered across net sales, profitability, and cash flow Net Sales Gross Margin Net Income Q1 2026 Q1 2026 Q1 2026 +3% YoY 63.5% $6.3M Tru Niagen +4% +10 bps Adj. EBITDA(1) $3.8M Cash & Liquidity 2026 Outlook (Updated) YTD 2026 Cash used fo
Slide 8: Financial Highlights
Financial Highlights The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019)
Slide 9: Q1 2026 Net Sales: $31.5M (+3% YoY)
Q1 2026 Net Sales: $31.5M (+3% YoY) Total Company: Total Company, excluding divested segment: +3% $31.5M Q1 2026 Q1 2025 +5% $30.5M $31.1M Tru Niagen $22.4M $21.5M $29.7M E-Commerce $19.2M $16.8M 23% 23% 23% 23% Watson's & Other B2B $3.2M $4.7M 10% 15% 10% Niagen Ingredients $8.2M $8.0M 15% Food-gra
Slide 10: 2025 – 2026 Net Sales Summary
2025 – 2026 Net Sales Summary ($ in millions) 2026 2025 Q1 Q1 Q2 Q3 Q4 FY Ecommerce 19.2 16.8 18.1 19.0 20.2 74.1 Watson’s & Other B2B 3.2 4.7 4.6 7.0 7.3 23.6 Total Tru Niagen 22.4 21.5 22.7 26.0 27.5 97.7 Food-grade Niagen 7.3 7.0 6.0 6.4 4.7 24.1 Pharmaceutical-grade Niagen 0.9 1.0 1.4 0.5 0.9 3.
Slide 11: Key P&L Metrics
Key P&L Metrics Three Months Ended March 31, ($ in thousands) 2026 2025 Net Sales 31,474 30,481 Gross Profit 19,976 19,331 % of Net Sales 63.5% 63.4% Sales and Marketing 9,675 8,117 % of Net Sales 30.7% 26.6% Research and Development 1,481 1,258 General and Administrative (1) 7,244 5,184 Operating I
Slide 12: Adjusted EBITDA Summary
Adjusted EBITDA Summary Reconciliation of Non-GAAP Financial Measures (In thousands) Three Months Ended FY Three Months Ended Q1 2025 Q2 2025 Q3 2025 Q4 2025 2025 Q1 2026 Net income, as reported $ 5,063 $ 3,609 $ 4,578 $ 4,132 $ 17,382 $ 6,318 Adjustments Interest income, net (459) (552) (564) (552)
Slide 13: Quarterly Balance Sheet Highlights
Quarterly Balance Sheet Highlights (in thousands) 3/31/25 6/30/25 9/30/25 12/31/25 3/31/26 Key Drivers (Q4 2025 vs Q1 2026) Up $1.8 million primarily driven by net income and proceeds from Cash $55,616 $60,474 $64,290 $64,788 $66,549 the sale of non-core business, partially offset by share repurchas
Slide 14: Cash Flow Highlights
Cash Flow Highlights Three Months Ended Three Months Ended FY 2025 (in thousands) 3/31/25 6/30/25 9/30/25 12/31/25 3/31/26 Net Income $5,063 $3,609 $4,578 $4,132 $17,382 $6,318 Working Capital 2,681 (4,399) (3,004) (3,669) (8,391) (5,017) Cash From / (Used for) Operations 7,883 1,250 3,692 679 13,50
Slide 15: 2026 Financial Outlook
2026 Financial Outlook 2025 Actual 2026 Full Year Outlook Key Drivers ($ in thousands) • Includes growth from E-commerce business and recurring Net Sales Increasing between 10-15% Y/Y $129,423 net sales from established partnerships (Net sales, excluding divested (excluding Analytical Reference Stan
Slide 16: The Science
The Science 16 The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019)
Slide 17: Scientific Advisory Board
Scientific Advisory Board 17
Slide 18: Clinical Studies on Oral Niagen in Multiple Health Areas
Clinical Studies on Oral Niagen® in Multiple Health Areas Note: Highlighted achievements in duration, participation, and dosage only consider peer-reviewed, published studies. Status of clinical studies presented as of April 24, 2026. 18
Slide 19: Contact Info
Contact Info: Niagen Bioscience Investor Relations: KCSA Strategic Communications Valter Pinto, Managing Director T: +1 (212) 896-1254 Niagen@kcsa.com www.niagenbioscience.com Where to purchase Tru Niagen® TruNiagen.com Find Health Clinics Offering Niagen® Plus NiagenPlus.com The information contain